JAFFER A AJANI to Female
This is a "connection" page, showing publications JAFFER A AJANI has written about Female.
Connection Strength
2.579
-
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023 05 20; 401(10389):1655-1668.
Score: 0.026
-
Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials. JAMA Oncol. 2022 10 01; 8(10):1456-1465.
Score: 0.025
-
Beyond Front-Line Therapy for Unresectable Gastroesophageal Adenocarcinoma: Are There Differences in Subsequent Therapy Sequencing? Oncology. 2022; 100(3):182-187.
Score: 0.023
-
Influence of Baseline Positron Emission Tomography in Metastatic Gastroesophageal Cancer on Survival and Response to Therapy. Oncology. 2021; 99(10):659-664.
Score: 0.023
-
Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Ann Surg. 2021 04 01; 273(4):751-757.
Score: 0.022
-
Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. Gut. 2021 12; 70(12):2238-2248.
Score: 0.022
-
Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut. 2021 11; 70(11):2055-2065.
Score: 0.022
-
Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification. Oncology. 2020; 98(12):884-888.
Score: 0.022
-
Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg. 2020 08; 272(2):311-318.
Score: 0.021
-
Low metabolic activity in primary gastric adenocarcinoma is associated with resistance to chemoradiation and the presence of signet ring cells. Surg Today. 2020 Oct; 50(10):1223-1231.
Score: 0.021
-
Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. Invest New Drugs. 2020 12; 38(6):1763-1773.
Score: 0.021
-
Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases. Gastric Cancer. 2020 09; 23(5):904-912.
Score: 0.021
-
Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer. Oncology. 2020; 98(5):289-294.
Score: 0.021
-
Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients. Medicine (Baltimore). 2020 Feb; 99(9):e19295.
Score: 0.021
-
Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020 01; 69(1):18-31.
Score: 0.020
-
Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma. Oncology. 2019; 96(5):252-258.
Score: 0.019
-
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. Eur J Cancer. 2019 02; 108:17-24.
Score: 0.019
-
Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. Oncology. 2018; 95(2):81-90.
Score: 0.018
-
Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology. 2018; 94(6):345-353.
Score: 0.018
-
A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. Am J Clin Oncol. 2018 04; 41(4):321-325.
Score: 0.018
-
Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. Target Oncol. 2018 02; 13(1):99-106.
Score: 0.018
-
Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. Br J Cancer. 2018 02 06; 118(3):331-337.
Score: 0.018
-
Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors. Br J Cancer. 2018 01; 118(1):52-61.
Score: 0.018
-
Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017 Nov 01; 123(21):4106-4113.
Score: 0.017
-
A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol. 2017 Sep 01; 28(9):2142-2148.
Score: 0.017
-
Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer. 2018 Jan; 21(1):31-40.
Score: 0.017
-
Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma. Ann Surg Oncol. 2017 Oct; 24(11):3338-3344.
Score: 0.017
-
Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. Br J Cancer. 2017 Aug 22; 117(5):648-655.
Score: 0.017
-
101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. Oncology. 2017; 93(4):243-248.
Score: 0.017
-
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. J Oncol Pract. 2017 01; 13(1):53-57.
Score: 0.017
-
Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. Ann Surg Oncol. 2017 Aug; 24(8):2291-2301.
Score: 0.016
-
Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors. Oncology. 2016; 91(1):55-60.
Score: 0.016
-
Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. Ann Surg Oncol. 2016 06; 23(6):1948-55.
Score: 0.016
-
A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. J Natl Compr Canc Netw. 2016 02; 14(2):173-9.
Score: 0.016
-
Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases. J Surg Oncol. 2016 Jan; 113(1):29-35.
Score: 0.015
-
Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. Oncology. 2016; 90(1):10-20.
Score: 0.015
-
Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. Oncology. 2015; 89(6):305-10.
Score: 0.015
-
18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer. 2015 Nov; 51(17):2545-52.
Score: 0.015
-
Early versus Delayed Therapy of Advanced Gastric Cancer Patients--Does It Make a Difference? Oncology. 2015; 89(4):215-20.
Score: 0.015
-
Time-to-Treatment Failure As the Primary End Point of a First-Line Advanced Gastric Cancer Randomized Trial: How Confused Would You Want Us to Be? J Clin Oncol. 2015 Jul 20; 33(21):2410.
Score: 0.015
-
Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. J Am Coll Surg. 2015 Jul; 221(1):83-90.
Score: 0.015
-
Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol. 2015 Jun; 111(7):875-81.
Score: 0.015
-
Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. Oncology. 2015; 88(6):332-6.
Score: 0.015
-
Cancer stem cells: the promise and the potential. Semin Oncol. 2015 Apr; 42 Suppl 1:S3-17.
Score: 0.015
-
Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol. 2014 Oct 20; 32(30):3400-5.
Score: 0.014
-
Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw. 2014 Aug; 12(8):1139-44.
Score: 0.014
-
Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology. 2014; 86(5-6):336-9.
Score: 0.014
-
Critical appraisal of locoregional failure and systemic disease progression after preoperative chemoradiation of esophageal adenocarcinoma. Reply to R. Gertler et al. J Clin Oncol. 2014 Jul 01; 32(19):2112-3.
Score: 0.014
-
Three angels are dancing on the head of the esophageal cancer pin, but shouldn't we not topple one or two? Ann Surg Oncol. 2014 Sep; 21(9):2815-6.
Score: 0.014
-
ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol. 2014 Feb; 8(1):142-9.
Score: 0.013
-
Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol. 2013 Dec 01; 31(34):4306-10.
Score: 0.013
-
Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology. 2013; 85(4):204-7.
Score: 0.013
-
Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Ann Oncol. 2013 Nov; 24(11):2854-9.
Score: 0.013
-
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013 Nov; 24(11):2844-9.
Score: 0.013
-
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer. 2013 Nov; 49(17):3616-24.
Score: 0.013
-
Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. Oncology. 2013; 85(2):95-9.
Score: 0.013
-
Challenges imposed by the complexity of cancer genome. Lancet Oncol. 2013 Jul; 14(8):e291-2.
Score: 0.013
-
Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol. 2013 May; 24(5):1262-6.
Score: 0.013
-
Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology. 2012; 83(5):300-4.
Score: 0.012
-
A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer. 2012 Dec; 48(18):3396-404.
Score: 0.012
-
Chemoradiation: Gastro-oesophageal cancer--is CROSSing over so hard to do? Nat Rev Clin Oncol. 2012 Sep; 9(9):493-4.
Score: 0.012
-
Localized gastric cancer treated with chemoradation without surgery: UTMD Anderson Cancer Center experience. Oncology. 2012; 82(6):347-51.
Score: 0.012
-
Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology. 2012; 82(2):108-13.
Score: 0.012
-
Preoperative chemotherapy for localized squamous cell carcinoma of the esophagus? We should go back to the drawing board! Ann Surg Oncol. 2012 Jan; 19(1):3-4.
Score: 0.012
-
Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus. 2012 Sep-Oct; 25(7):614-22.
Score: 0.012
-
Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012 May 15; 118(10):2632-40.
Score: 0.012
-
Modern approaches to localized cancer of the esophagus. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):902-11.
Score: 0.011
-
Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 2011 Nov 01; 117(21):4823-33.
Score: 0.011
-
An expert opinion on esophageal cancer therapy. Expert Opin Pharmacother. 2011 Feb; 12(2):225-39.
Score: 0.011
-
The influence of high body mass index on the prognosis of patients with esophageal cancer after surgery as primary therapy. Cancer. 2010 Dec 15; 116(24):5619-27.
Score: 0.011
-
Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer. 2011 Mar 01; 117(5):925-30.
Score: 0.011
-
Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer. 2010 Oct 01; 116(19):4487-94.
Score: 0.011
-
Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010 Sep 01; 116(17):4007-13.
Score: 0.011
-
Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg. 2010 Sep; 90(3):892-8; discussion 898-9.
Score: 0.011
-
The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology. 2010; 78(5-6):316-22.
Score: 0.011
-
Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010 Apr 01; 116(7):1656-63.
Score: 0.010
-
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010 Mar 20; 28(9):1547-53.
Score: 0.010
-
Association of age and survival in patients with gastroesophageal cancer undergoing surgery with or without preoperative therapy. Cancer. 2009 Oct 01; 115(19):4450-8.
Score: 0.010
-
Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer. 2009 Feb 01; 115(3):624-30.
Score: 0.010
-
US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol. 2009 Mar 01; 27(7):1116-21.
Score: 0.010
-
Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis Esophagus. 2009; 22(2):127-32.
Score: 0.009
-
Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation. Dis Esophagus. 2009; 22(1):32-41.
Score: 0.009
-
Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer. 2008 Sep 15; 113(6):1302-8.
Score: 0.009
-
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol. 2008 Oct 01; 26(28):4551-6.
Score: 0.009
-
Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction. Dis Esophagus. 2008; 21(7):575-81.
Score: 0.009
-
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008 Apr 23; 299(16):1914-21.
Score: 0.009
-
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008 Mar 10; 26(8):1316-23.
Score: 0.009
-
Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. Cancer. 2008 Mar 01; 112(5):1020-7.
Score: 0.009
-
Value of endoscopic ultrasound staging in conjunction with the evaluation of lymphovascular invasion in identifying low-risk esophageal carcinoma. Cancer. 2008 Feb 01; 112(3):503-10.
Score: 0.009
-
Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer. 2007 Nov 15; 110(10):2186-90.
Score: 0.009
-
Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer. 2007 Sep 01; 110(5):989-95.
Score: 0.009
-
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007 Aug 01; 25(22):3210-6.
Score: 0.009
-
Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-kappaB expression. Cancer Epidemiol Biomarkers Prev. 2007 Jun; 16(6):1200-5.
Score: 0.009
-
The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma. Cancer. 2007 May 15; 109(10):1989-95.
Score: 0.009
-
Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J Clin Oncol. 2007 Feb 20; 25(6):698-707.
Score: 0.008
-
[Expression of transcription factor Sp1 in human gastric cancer tissue and its correlation with prognosis]. Zhonghua Zhong Liu Za Zhi. 2007 Feb; 29(2):107-11.
Score: 0.008
-
Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer. 2007 Jan 01; 109(1):33-40.
Score: 0.008
-
Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 01; 13(1):234-40.
Score: 0.008
-
Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer. 2006 Dec 01; 107(11):2576-80.
Score: 0.008
-
Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther. 2006 Nov; 5(11):2844-50.
Score: 0.008
-
Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer. 2006 Oct 01; 107(7):1475-82.
Score: 0.008
-
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs. 2006 Sep; 24(5):441-6.
Score: 0.008
-
Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006 Aug 20; 24(24):3953-8.
Score: 0.008
-
Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Br J Cancer. 2006 Aug 21; 95(4):450-6.
Score: 0.008
-
A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs. 2006 Jul; 24(4):353-7.
Score: 0.008
-
Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006 Aug 10; 24(23):3789-98.
Score: 0.008
-
An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer. 2006 May 01; 106(9):1908-16.
Score: 0.008
-
Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer. 2006 Feb 01; 106(3):552-8.
Score: 0.008
-
Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006 Feb 01; 24(4):663-7.
Score: 0.008
-
Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol. 2006 Feb 10; 24(5):748-54.
Score: 0.008
-
Gender-based analysis of esophageal cancer patients undergoing preoperative chemoradiation: differences in presentation and therapy outcome. Dis Esophagus. 2006; 19(3):152-7.
Score: 0.008
-
Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2006 Jan 10; 24(2):259-67.
Score: 0.008
-
Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005 Dec 01; 104(11):2365-72.
Score: 0.008
-
Impact of cyclin D1 A870G polymorphism in esophageal adenocarcinoma tumorigenesis. Semin Oncol. 2005 Dec; 32(6 Suppl 9):S11-5.
Score: 0.008
-
Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer. 2005 Oct 15; 104(8):1620-6.
Score: 0.008
-
Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer. 2005 Oct 01; 104(7):1349-55.
Score: 0.008
-
A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Invest New Drugs. 2005 Oct; 23(5):479-84.
Score: 0.008
-
Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol. 2005 Oct 01; 23(28):6957-65.
Score: 0.008
-
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005 Aug 20; 23(24):5660-7.
Score: 0.008
-
Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. Am J Ophthalmol. 2005 Aug; 140(2):325-7.
Score: 0.008
-
Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol. 2005 May 01; 23(13):3094-103.
Score: 0.007
-
Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005 Feb 20; 23(6):1237-44.
Score: 0.007
-
Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. Int J Gastrointest Cancer. 2005; 36(2):69-76.
Score: 0.007
-
Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004 Aug 01; 101(3):518-26.
Score: 0.007
-
Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004 Jul 15; 22(14):2774-80.
Score: 0.007
-
Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer. 2004 Jun 01; 100(11):2347-54.
Score: 0.007
-
S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study. Jpn J Clin Oncol. 2004 May; 34(5):282-6.
Score: 0.007
-
Chemotherapy is more active against proximal than distal gastric carcinoma. Oncology. 2004; 66(4):269-74.
Score: 0.007
-
Gastric cancer: advances in adjuvant and adjunct therapy. Curr Treat Options Oncol. 2003 Oct; 4(5):413-9.
Score: 0.007
-
Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):20-2.
Score: 0.007
-
Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003 Jul-Aug; 9(4):261-7.
Score: 0.007
-
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023 07; 24(7):744-756.
Score: 0.006
-
How much progress have we made?: a 20-year experience regarding esophageal stents for the palliation of malignant dysphagia. Dis Esophagus. 2022 Jun 15; 35(6).
Score: 0.006
-
Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Williston Park). 2002 May; 16(5 Suppl 5):16-8.
Score: 0.006
-
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med. 2022 02 03; 386(5):449-462.
Score: 0.006
-
CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer. 2002 Feb 01; 94(3):641-6.
Score: 0.006
-
Therapy of localized gastric cancer: preoperative and postoperative approaches. Ann Oncol. 2002; 13 Suppl 4:7-12.
Score: 0.006
-
Docetaxel in combination for advanced gastric cancer. Gastric Cancer. 2002; 5 Suppl 1:31-4.
Score: 0.006
-
Genome-wide host methylation profiling of anal and cervical carcinoma. PLoS One. 2021; 16(12):e0260857.
Score: 0.006
-
Analysis of trimodal and bimodal therapy in a selective-surgery paradigm for locally advanced oesophageal squamous cell carcinoma. Br J Surg. 2021 10 23; 108(10):1207-1215.
Score: 0.006
-
Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis. Ann Surg. 2021 10 01; 274(4):544-548.
Score: 0.006
-
A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer. 2001 Jul 15; 92(2):279-86.
Score: 0.006
-
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 07 03; 398(10294):27-40.
Score: 0.006
-
Benchmarks for nodal yield and ratio for node-positive gastric cancer. Surgery. 2021 10; 170(4):1231-1239.
Score: 0.006
-
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021 04 01; 384(13):1191-1203.
Score: 0.006
-
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). J Clin Oncol. 2021 03 20; 39(9):990-1000.
Score: 0.006
-
Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol. 2001 Feb; 24(1):91-5.
Score: 0.006
-
Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. J Surg Oncol. 2021 Mar; 123(4):911-922.
Score: 0.005
-
Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med. 2021 01; 27(1):141-151.
Score: 0.005
-
Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea. Invest New Drugs. 2001; 19(4):341-3.
Score: 0.005
-
Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma. Br J Cancer. 2021 03; 124(5):963-974.
Score: 0.005
-
Comparison of laparoscopy versus mini-laparotomy for jejunostomy placement in patients with gastric adenocarcinoma. Surg Endosc. 2021 12; 35(12):6577-6582.
Score: 0.005
-
Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer. Cancer Sci. 2020 Nov; 111(11):4205-4217.
Score: 0.005
-
Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. J Thorac Cardiovasc Surg. 2021 Nov; 162(5):1404-1412.e2.
Score: 0.005
-
Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer. 2011 Jan 01; 117(1):63-9.
Score: 0.005
-
Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. Ann Thorac Surg. 2021 04; 111(4):1133-1140.
Score: 0.005
-
Relationship between initial management strategy and survival in patients with gastric outlet obstruction due to gastric cancer. J Surg Oncol. 2020 Dec; 122(7):1373-1382.
Score: 0.005
-
The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology. 2020 12; 159(6):2146-2162.e33.
Score: 0.005
-
Laparoscopic HIPEC for Low-Volume Peritoneal Metastasis in Gastric and Gastroesophageal Adenocarcinoma. Ann Surg Oncol. 2020 Dec; 27(13):5047-5056.
Score: 0.005
-
Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection. Br J Cancer. 2020 10; 123(8):1244-1252.
Score: 0.005
-
Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience. Ann Surg Oncol. 2021 Feb; 28(2):758-765.
Score: 0.005
-
Epstein-Barr virus-associated gastric cancer: disease that requires special approach. Gastric Cancer. 2020 11; 23(6):951-960.
Score: 0.005
-
Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. J Surg Oncol. 2020 Sep; 122(3):422-432.
Score: 0.005
-
Efficacy of Three-Drug Induction Chemotherapy Followed by Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma. Oncology. 2020; 98(8):542-548.
Score: 0.005
-
Preoperative Chemoradiation Versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma. Ann Thorac Surg. 2020 08; 110(2):398-405.
Score: 0.005
-
Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience. Dis Esophagus. 2020 Mar 16; 33(3).
Score: 0.005
-
Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020 05 10; 38(14):1569-1579.
Score: 0.005
-
A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J. 2000 Mar-Apr; 6(2):78-81.
Score: 0.005
-
Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma. World J Surg Oncol. 2020 Feb 17; 18(1):39.
Score: 0.005
-
Small cell carcinoma of the esophagus: the University of Texas M. D. Anderson Cancer Center experience and literature review. Cancer. 2000 Jan 15; 88(2):262-7.
Score: 0.005
-
A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. Dis Model Mech. 2019 12 17; 12(12).
Score: 0.005
-
Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncol. 2019 11 01; 5(11):1597-1604.
Score: 0.005
-
Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer. J Surg Oncol. 2019 Dec; 120(8):1350-1357.
Score: 0.005
-
Prognostic Value of Lymph Node Yield After Neoadjuvant Chemoradiation for Gastric Cancer. Ann Surg Oncol. 2020 Feb; 27(2):534-542.
Score: 0.005
-
Gastric cancer in the remnant stomach after pancreaticoduodenectomy: A case series. J Surg Oncol. 2019 Dec; 120(7):1137-1141.
Score: 0.005
-
Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Gastric Cancer. 2020 01; 23(1):95-104.
Score: 0.005
-
Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol. 1999 Aug; 17(8):2403-11.
Score: 0.005
-
Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Ann Surg Oncol. 2019 Oct; 26(11):3602-3610.
Score: 0.005
-
Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma. Cancer. 1999 Jun 01; 85(11):2336-9.
Score: 0.005
-
The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors. Gastric Cancer. 2019 11; 22(6):1100-1108.
Score: 0.005
-
Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999 Mar; 229(3):303-8.
Score: 0.005
-
Oral etoposide for patients with metastatic gastric adenocarcinoma. Cancer J Sci Am. 1999 Mar-Apr; 5(2):112-4.
Score: 0.005
-
Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer. Gastric Cancer. 2019 07; 22(4):803-816.
Score: 0.005
-
Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy. Ann Surg Oncol. 2019 May; 26(5):1394-1400.
Score: 0.005
-
Serum miR-331-3p predicts tumor recurrence in esophageal adenocarcinoma. Sci Rep. 2018 09 18; 8(1):14006.
Score: 0.005
-
Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg. 2018 08; 268(2):289-295.
Score: 0.005
-
Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of Technique. J Gastrointest Surg. 2018 11; 22(11):2013-2019.
Score: 0.005
-
Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor Oncologic Outcomes in Patients with Complications After Gastrectomy. Ann Surg Oncol. 2018 Sep; 25(9):2720-2730.
Score: 0.005
-
Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am. 1998 Jul-Aug; 4(4):269-74.
Score: 0.005
-
The ypT category does not impact overall survival in node negative gastric cancer. J Surg Oncol. 2018 Jun; 117(8):1721-1728.
Score: 0.005
-
Repeat staging laparoscopy for gastric cancer after preoperative therapy. J Surg Oncol. 2018 Jul; 118(1):61-67.
Score: 0.005
-
Potentially curable gastric adenocarcinoma treated without surgery. Eur J Cancer. 2018 07; 98:23-29.
Score: 0.005
-
Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved. Ann Surg Oncol. 2018 Jul; 25(7):2012-2017.
Score: 0.005
-
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018 05; 24(5):556-562.
Score: 0.005
-
Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. Gastric Cancer. 2018 11; 21(6):1004-1013.
Score: 0.005
-
Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun. 2018 05 03; 9(1):1777.
Score: 0.005
-
Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy. J Gastrointest Surg. 2018 08; 22(8):1325-1333.
Score: 0.005
-
Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2018 07; 156(1):406-413.e3.
Score: 0.005
-
Pyloroplasty may reduce weight loss 1 year after esophagectomy. Dis Esophagus. 2018 Mar 01; 31(3).
Score: 0.005
-
Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014. Cancer. 2018 03 01; 124(5):998-1007.
Score: 0.004
-
Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol. 1998 Feb; 21(1):36-8.
Score: 0.004
-
Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma. Invest New Drugs. 1998; 16(2):175-7.
Score: 0.004
-
Oral etoposide for patients with advanced adenocarcinoma of the pancreas. Invest New Drugs. 1998-1999; 16(4):333-5.
Score: 0.004
-
Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 2018 07; 128(1):154-160.
Score: 0.004
-
Clinical features and survival of gastric cancer patients with DNA mismatch repair deficiency. J Surg Oncol. 2018 Mar; 117(4):707-709.
Score: 0.004
-
Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma. J Surg Oncol. 2018 Mar; 117(4):678-684.
Score: 0.004
-
Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. Am J Clin Oncol. 1997 Dec; 20(6):573-6.
Score: 0.004
-
Treatment of patients with upper gastrointestinal carcinomas. Semin Oncol. 1997 Dec; 24(6 Suppl 19):S19-72-S19-76.
Score: 0.004
-
The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. Gastric Cancer. 2018 Jan; 21(1):1-9.
Score: 0.004
-
Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database. Ann Surg Oncol. 2017 Nov; 24(12):3683-3691.
Score: 0.004
-
Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer. J Gastrointest Surg. 2017 Oct; 21(10):1563-1570.
Score: 0.004
-
Preoperative Chemoradiation Therapy Does Not Increase Risk of Anastomotic Leak in Patients With Gastric Cancer. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):660-666.
Score: 0.004
-
Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Mol Cancer Ther. 2017 10; 16(10):2215-2222.
Score: 0.004
-
Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. Med Oncol. 2017 Aug; 34(8):135.
Score: 0.004
-
Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clin Cancer Res. 2017 Oct 01; 23(19):5671-5678.
Score: 0.004
-
Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):667-676.
Score: 0.004
-
Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer. 2018 Jan; 21(1):74-83.
Score: 0.004
-
Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017 Apr 25; 8(17):28696-28710.
Score: 0.004
-
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017 05; 18(5):640-653.
Score: 0.004
-
Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol. 2017 Sep; 24(9):2679-2687.
Score: 0.004
-
D-mannose: a novel prognostic biomarker for patients with esophageal adenocarcinoma. Carcinogenesis. 2017 02 01; 38(2):162-167.
Score: 0.004
-
Early clinical esophageal adenocarcinoma (cT1): Utility of CT in regional nodal metastasis detection and can the clinical accuracy be improved? Eur J Radiol. 2017 Mar; 88:56-60.
Score: 0.004
-
Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):554-562.
Score: 0.004
-
Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol. 2017 02; 12(2):375-382.
Score: 0.004
-
Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer. Ann Surg Oncol. 2017 Apr; 24(4):960-965.
Score: 0.004
-
Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas. Semin Oncol. 1996 Oct; 23(5 Suppl 12):55-8.
Score: 0.004
-
Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. Clin Cancer Res. 2016 Dec 15; 22(24):6228-6235.
Score: 0.004
-
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer. 2016 10 11; 115(8):974-982.
Score: 0.004
-
Survival rates in T1 and T2 gastric cancer: A Western report. J Surg Oncol. 2016 Oct; 114(5):602-606.
Score: 0.004
-
Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Ann Surg Oncol. 2016 12; 23(13):4332-4337.
Score: 0.004
-
The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology. 2016; 90(5):239-47.
Score: 0.004
-
Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. Ann Thorac Surg. 2016 Mar; 101(3):1075-80; Discussion 1080-1.
Score: 0.004
-
Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ? Ann Surg Oncol. 2016 Feb; 23(2):626-32.
Score: 0.004
-
Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy. J Surg Oncol. 2015 Dec; 112(8):883-7.
Score: 0.004
-
The activity of paclitaxel in gastrointestinal tumors. Semin Oncol. 1995 Oct; 22(5 Suppl 12):46-50; discussion 51-3.
Score: 0.004
-
Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. Ann Surg Oncol. 2016 Jan; 23(1):156-62.
Score: 0.004
-
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). J Gastrointest Cancer. 2015 Jun; 46(2):109-17.
Score: 0.004
-
Paclitaxel in the treatment of carcinoma of the esophagus. Semin Oncol. 1995 Jun; 22(3 Suppl 6):35-40.
Score: 0.004
-
Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling. Clin Gastroenterol Hepatol. 2015 Oct; 13(10):1730-1737.e9.
Score: 0.004
-
Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. Oncology. 2015; 89(2):65-9.
Score: 0.004
-
Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction. Eur J Cancer. 1995; 31A(5):665-70.
Score: 0.004
-
Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut. 2015 Nov; 64(11):1721-31.
Score: 0.004
-
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct; 15(11):1224-35.
Score: 0.004
-
A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. Cancer. 2014 Dec 01; 120(23):3635-41.
Score: 0.004
-
Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study. Dis Colon Rectum. 2014 Aug; 57(8):941-57.
Score: 0.004
-
Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994 Jul 20; 86(14):1086-91.
Score: 0.004
-
Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation. Ann Thorac Surg. 2014 Sep; 98(3):1064-71.
Score: 0.004
-
Potentially functional variants in the core nucleotide excision repair genes predict survival in Japanese gastric cancer patients. Carcinogenesis. 2014 Sep; 35(9):2031-8.
Score: 0.003
-
Genetic and intermediate phenotypic susceptibility markers of gastric cancer in Hispanic Americans: a case-control study. Cancer. 2014 Oct 01; 120(19):3040-8.
Score: 0.003
-
Genetic polymorphisms in the microRNA binding-sites of the thymidylate synthase gene predict risk and survival in gastric cancer. Mol Carcinog. 2015 Sep; 54(9):880-8.
Score: 0.003
-
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014 Apr 15; 5(7):1837-45.
Score: 0.003
-
Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. J Natl Cancer Inst. 1994 Jan 05; 86(1):51-3.
Score: 0.003
-
Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst. 1993 Nov 17; 85(22):1839-44.
Score: 0.003
-
Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2014 Jan; 21(1):306-14.
Score: 0.003
-
Concordance of studies for nodal staging is prognostic for worse survival in esophageal cancer. Dis Esophagus. 2014 Nov-Dec; 27(8):770-6.
Score: 0.003
-
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013 Nov 01; 31(31):3935-43.
Score: 0.003
-
ERCC1 and ERCC2 variants predict survival in gastric cancer patients. PLoS One. 2013; 8(9):e71994.
Score: 0.003
-
Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013 Aug 01; 86(5):885-91.
Score: 0.003
-
Risk assessment of esophageal adenocarcinoma using ?-H2AX assay. Cancer Epidemiol Biomarkers Prev. 2013 Oct; 22(10):1797-804.
Score: 0.003
-
Association of mitochondrial DNA copy number in peripheral blood leukocytes with risk of esophageal adenocarcinoma. Carcinogenesis. 2013 Nov; 34(11):2521-4.
Score: 0.003
-
Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg. 2013 Aug; 17(8):1359-69.
Score: 0.003
-
The miR-184 binding-site rs8126 T>C polymorphism in TNFAIP2 is associated with risk of gastric cancer. PLoS One. 2013; 8(5):e64973.
Score: 0.003
-
Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. Dis Esophagus. 2014 Feb-Mar; 27(2):168-75.
Score: 0.003
-
MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila). 2013 Mar; 6(3):196-205.
Score: 0.003
-
Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. Invest New Drugs. 1993 Feb; 11(1):67-9.
Score: 0.003
-
Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting. Dis Esophagus. 2013 Sep-Oct; 26(7):708-15.
Score: 0.003
-
Response to increasing doses of octreotide in a patient with carcinoid syndrome. Eur J Cancer. 1993; 29A(16):2332-3.
Score: 0.003
-
Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 1993 Jan; 11(1):22-8.
Score: 0.003
-
Evaluation of oral etoposide in patients with metastatic gastric carcinoma: a preliminary report. Semin Oncol. 1992 Dec; 19(6 Suppl 14):45-7.
Score: 0.003
-
Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012 Dec 10; 30(35):4344-51.
Score: 0.003
-
Minimally invasive versus open oesophagectomy for oesophageal cancer. Lancet. 2012 Sep 08; 380(9845):883; author reply 885-6.
Score: 0.003
-
Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. 2013 Jun; 52(5):1002-9.
Score: 0.003
-
Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. Ann Thorac Surg. 2012 Oct; 94(4):1126-32; discussion 1132-3.
Score: 0.003
-
Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1078-85.
Score: 0.003
-
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012 Jul 01; 30(19):2327-33.
Score: 0.003
-
Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):e231-9.
Score: 0.003
-
Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e345-51.
Score: 0.003
-
Prolonged chemotherapy for localised squamous carcinoma of the oesophagus. Eur J Cancer. 1992; 28A(4-5):880-4.
Score: 0.003
-
Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer. 2012 Sep 01; 118(17):4346-53.
Score: 0.003
-
Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):581-6.
Score: 0.003
-
Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas. Invest New Drugs. 1991 Nov; 9(4):369-71.
Score: 0.003
-
Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther. 2011 Dec; 10(12):2350-62.
Score: 0.003
-
Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg. 2012 Jan; 93(1):207-12; discussion 212-3.
Score: 0.003
-
Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer. 1991 Oct 01; 68(7):1501-6.
Score: 0.003
-
Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma. Invest New Drugs. 1991 Aug; 9(3):257-9.
Score: 0.003
-
Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma. Am J Surg Pathol. 2011 Jul; 35(7):1045-53.
Score: 0.003
-
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011 Aug; 141(2):476-85, 485.e1-11.
Score: 0.003
-
A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):1967-72.
Score: 0.003
-
Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res. 2011 Apr 01; 17(7):1850-7.
Score: 0.003
-
Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer. 2011 Jan 01; 128(1):132-43.
Score: 0.003
-
Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One. 2010 Nov 30; 5(11):e15074.
Score: 0.003
-
Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol. 2010 Dec 01; 28(34):5061-6.
Score: 0.003
-
Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg. 2010 Sep; 90(3):884-90; discussion 890-1.
Score: 0.003
-
Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila). 2010 Sep; 3(9):1176-86.
Score: 0.003
-
Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 1990 Jul; 8(7):1231-8.
Score: 0.003
-
Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315. J Natl Cancer Inst. 2010 Apr 21; 102(8):547-56.
Score: 0.003
-
Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. 2010 Mar 15; 116(6):1446-53.
Score: 0.003
-
A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. Cancer Invest. 1990; 8(6):619-21.
Score: 0.003
-
The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer. BMC Gastroenterol. 2009 Oct 16; 9:77.
Score: 0.003
-
MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res. 2009 Sep 15; 15(18):5744-52.
Score: 0.003
-
Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. Mod Pathol. 2009 Dec; 22(12):1612-21.
Score: 0.003
-
Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med. 1989 Aug; 87(2):221-4.
Score: 0.002
-
Outcomes with esophageal cancer radiation therapy. J Thorac Oncol. 2009 Jul; 4(7):880-8.
Score: 0.002
-
Induction and concurrent taxanes enhance both the pulmonary metabolic radiation response and the radiation pneumonitis response in patients with esophagus cancer. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):816-23.
Score: 0.002
-
Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer. Cancer Prev Res (Phila). 2009 May; 2(5):459-65.
Score: 0.002
-
Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2009 Oct; 138(4):831-6.
Score: 0.002
-
Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. J Biol Response Mod. 1989 Apr; 8(2):140-6.
Score: 0.002
-
Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer. 2009 Apr 01; 115(7):1576-85.
Score: 0.002
-
Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort. Int J Radiat Oncol Biol Phys. 2009 Jun 01; 74(2):482-9.
Score: 0.002
-
Esophageal tumor length is independently associated with long-term survival. Cancer. 2009 Feb 01; 115(3):508-16.
Score: 0.002
-
Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol. 2009 Feb 20; 27(6):857-71.
Score: 0.002
-
Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. Cancer Chemother Pharmacol. 1989; 24(1):41-4.
Score: 0.002
-
Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila). 2008 Nov; 1(6):460-9.
Score: 0.002
-
Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol. 1988 Nov; 6(11):1703-7.
Score: 0.002
-
NCCN practice guidelines for upper gastrointestinal carcinomas. National Comprehensive Cancer Network. Oncology (Williston Park). 1998 Nov; 12(11A):179-223.
Score: 0.002
-
Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer. 2008 Oct 15; 113(8):2038-45.
Score: 0.002
-
Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008 Sep; 32(9):1404-11.
Score: 0.002
-
Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. Int J Radiat Oncol Biol Phys. 2008 May 01; 71(1):167-72.
Score: 0.002
-
A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan; 63(2):363-70.
Score: 0.002
-
Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma. Invest New Drugs. 1988 Apr; 6(1):47-50.
Score: 0.002
-
Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med. 1988 Mar; 108(3):340-4.
Score: 0.002
-
Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Thorac Oncol. 2008 Mar; 3(3):277-82.
Score: 0.002
-
Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol. 2008; 47(3):421-7.
Score: 0.002
-
Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):741-7.
Score: 0.002
-
Comparison between clinical response and in vitro drug sensitivity of primary human tumors in the adhesive tumor cell culture system. J Clin Oncol. 1987 Dec; 5(12):1912-21.
Score: 0.002
-
Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol. 2007 Nov; 31(11):1719-25.
Score: 0.002
-
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007 Aug 20; 25(24):3719-25.
Score: 0.002
-
Radiation pneumonitis: local dose versus [18F]-fluorodeoxyglucose uptake response in irradiated lung. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1030-5.
Score: 0.002
-
Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):794-800.
Score: 0.002
-
Treatment of gastric adenocarcinoma may differ among hospital types in the United States, a report from theNational Cancer Data Base. J Gastrointest Surg. 2007 Apr; 11(4):410-9; discussion 419-20.
Score: 0.002
-
Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol. 2007 Jul; 14(7):2010-7.
Score: 0.002
-
Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer. 2007 Feb 15; 109(4):658-67.
Score: 0.002
-
Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res. 2007 Feb 01; 13(3):912-9.
Score: 0.002
-
Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer. 2007 Jan 01; 109(1):125-34.
Score: 0.002
-
Evolving role of self-expanding metal stents in the treatment of malignant dysphagia and fistulas. Gastrointest Endosc. 2007 Jan; 65(1):70-6.
Score: 0.002
-
Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol. 2007 Jan; 31(1):58-64.
Score: 0.002
-
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006 Nov 01; 24(31):4991-7.
Score: 0.002
-
Deficiency of cell cycle checkpoints and DNA repair system predispose individuals to esophageal cancer. Mutat Res. 2006 Dec 01; 602(1-2):143-50.
Score: 0.002
-
The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation. Cancer. 2006 Oct 01; 107(7):1467-74.
Score: 0.002
-
Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. World J Gastroenterol. 2006 Sep 14; 12(34):5501-8.
Score: 0.002
-
The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer. 2006 Sep 01; 107(5):967-74.
Score: 0.002
-
Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res. 2006 Aug 01; 12(15):4598-604.
Score: 0.002
-
Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol. 2006 Jun; 1(5):478-86.
Score: 0.002
-
Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas. Cancer Treat Rep. 1986 Mar; 70(3):375-9.
Score: 0.002
-
The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer. 2006 Mar 01; 106(5):1017-25.
Score: 0.002
-
Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience. J Thorac Oncol. 2006 Mar; 1(3):252-9.
Score: 0.002
-
Neuroendocrine tumors. J Natl Compr Canc Netw. 2006 Feb; 4(2):102-38.
Score: 0.002
-
Activity of 2-fluoro-Ara AMP against gynecologic tumors in the soft agar assay. Invest New Drugs. 1986; 4(2):141-8.
Score: 0.002
-
Phase II study of spirogermanium in patients with advanced colorectal carcinoma. Invest New Drugs. 1986; 4(4):383-5.
Score: 0.002
-
Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2006 Jan; 131(1):65-72.
Score: 0.002
-
Predictors of esophageal cancer risk: assessment of susceptibility to DNA damage using comet assay. Genes Chromosomes Cancer. 2005 Dec; 44(4):415-22.
Score: 0.002
-
Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys. 2006 Mar 01; 64(3):700-8.
Score: 0.002
-
Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2006 Mar 01; 64(3):692-9.
Score: 0.002
-
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005 Oct 15; 104(8):1590-602.
Score: 0.002
-
Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol. 2005 Aug; 29(8):1079-85.
Score: 0.002
-
Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005 May; 241(5):810-7; discussion 817-20.
Score: 0.002
-
Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux. Ann Thorac Surg. 2005 May; 79(5):1716-23.
Score: 0.002
-
Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005 Apr 01; 103(7):1347-55.
Score: 0.002
-
Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res. 2005 Mar 15; 11(6):2229-36.
Score: 0.002
-
Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 01; 61(3):656-64.
Score: 0.002
-
Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res. 2005 Feb 15; 11(4):1386-93.
Score: 0.002
-
Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg. 2005 Feb; 79(2):391-7; discussionn 391-7.
Score: 0.002
-
Sequential methotrexate and 5-fluorouracil in the primary treatment of metastatic colorectal carcinoma. Am J Clin Oncol. 1985 Feb; 8(1):69-71.
Score: 0.002
-
Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis. 2005 Apr; 26(4):785-91.
Score: 0.002
-
Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):656-63.
Score: 0.002
-
Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer. 2005; 8(1):18-28.
Score: 0.002
-
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004 Dec 01; 22(23):4762-71.
Score: 0.002
-
Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2004 Dec 01; 60(5):1484-93.
Score: 0.002
-
2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004 Oct 15; 101(8):1776-85.
Score: 0.002
-
Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004 Oct 01; 60(2):427-36.
Score: 0.002
-
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004 Oct; 78(4):1152-60; discussion 1152-60.
Score: 0.002
-
Treatment issues in pediatric gastric adenocarcinoma. J Pediatr Surg. 2004 Aug; 39(8):e8-10.
Score: 0.002
-
Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol. 2004 Jul; 99(7):1258-66.
Score: 0.002
-
Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4109-17.
Score: 0.002
-
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004 May 15; 22(10):1785-96.
Score: 0.002
-
Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus. 2004; 17(1):38-43.
Score: 0.002
-
A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis. 2004; 21(8):755-64.
Score: 0.002
-
Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003 Dec 15; 9(17):6371-80.
Score: 0.002
-
Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys. 2003 Dec 01; 57(5):1317-22.
Score: 0.002
-
Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2003 Sep 01; 57(1):120-7.
Score: 0.002
-
Leptomeningeal carcinomatosis originating from gastric cancer: report of eight cases and review of the literature. Am J Clin Oncol. 2003 Apr; 26(2):165-70.
Score: 0.002
-
Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer. 2003 Mar 01; 97(5):1195-202.
Score: 0.002
-
Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res. 2003 Jan; 9(1):134-42.
Score: 0.002
-
Multiple squamous cell carcinoma treated with intra-arterial cisplatin in a patient with rheumatoid arthritis. Cancer Treat Rep. 1982 Nov; 66(11):1987-9.
Score: 0.002
-
Treatment outcomes of resected esophageal cancer. Ann Surg. 2002 Sep; 236(3):376-84; discussion 384-5.
Score: 0.002
-
Outcomes after emergency surgery for gastric perforation or severe bleeding in patients with gastric cancer. J Surg Oncol. 2002 Aug; 80(4):181-5.
Score: 0.002
-
Management of perforated gastric carcinoma: a report of 16 cases and review of world literature. Am Surg. 2002 May; 68(5):434-40.
Score: 0.002
-
Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002 Jan; 123(1):175-83.
Score: 0.001
-
Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001 Dec; 130(6):1078-85.
Score: 0.001
-
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 06; 345(10):725-30.
Score: 0.001
-
A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol. 2001 Jul; 8(6):519-24.
Score: 0.001
-
Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg. 2000 Jun; 119(6):1126-32.
Score: 0.001
-
Gastric cancer and metastasis to the brain. Ann Surg Oncol. 1999 Dec; 6(8):771-6.
Score: 0.001
-
Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol. 1999 May; 51(2):153-60.
Score: 0.001
-
Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999 Feb; 17(2):600-6.
Score: 0.001
-
Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest. 1999; 17(7):474-8.
Score: 0.001
-
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998 Dec 31; 339(27):1979-84.
Score: 0.001
-
Palliation of malignant dysphagia and fistulae with coated expandable metal stents: experience with 101 patients. Gastrointest Endosc. 1998 Aug; 48(2):172-9.
Score: 0.001
-
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998 May; 16(5):1826-34.
Score: 0.001
-
Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR Am J Roentgenol. 1998 Feb; 170(2):339-44.
Score: 0.001
-
Mutation of the hMSH2 gene in two families with hereditary nonpolyposis colorectal cancer. Hum Mutat. 1996; 7(4):327-33.
Score: 0.001
-
Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. Am J Clin Oncol. 1995 Oct; 18(5):436-8.
Score: 0.001
-
Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys. 1995 Jul 15; 32(4):1025-9.
Score: 0.001
-
Preoperative infusional chemoradiation and surgery with or without an electron beam intraoperative boost for advanced primary rectal cancer. Int J Radiat Oncol Biol Phys. 1995 Apr 30; 32(1):197-204.
Score: 0.001
-
Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. Cancer. 1995 Jan 15; 75(2):451-6.
Score: 0.001
-
Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol. 1994 Nov; 12(11):2296-300.
Score: 0.001
-
A phase II trial of paclitaxel (Taxol) in advanced esophageal cancer: preliminary report. Semin Oncol. 1994 Oct; 21(5 Suppl 8):44-8.
Score: 0.001
-
Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. Ann Oncol. 1994 May; 5(5):468-70.
Score: 0.001
-
Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal carcinoma. Ann Surg Oncol. 1994 Mar; 1(2):111-6.
Score: 0.001
-
Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Ann Oncol. 1994 Mar; 5(3):286-7.
Score: 0.001
-
Nonfunctioning islet cell carcinoma of the pancreas. Surgery. 1993 Dec; 114(6):1175-81; discussion 1181-2.
Score: 0.001
-
A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. Cancer. 1993 Nov 01; 72(9):2560-3.
Score: 0.001
-
Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin. Radiother Oncol. 1993 Jun; 27(3):209-15.
Score: 0.001
-
Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity. Cancer. 1993 Jun 01; 71(11):3690-6.
Score: 0.001
-
Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. Cancer. 1993 Feb 15; 71(4):1214-8.
Score: 0.001
-
A phase II study of merbarone in patients with adenocarcinoma of the pancreas. Cancer Invest. 1993; 11(6):667-9.
Score: 0.001
-
Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am J Clin Oncol. 1992 Dec; 15(6):524-7.
Score: 0.001
-
Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer. 1992 Oct 15; 70(8):2073-6.
Score: 0.001
-
Phase II study of didemnin B in advanced colorectal cancer. Invest New Drugs. 1992 Aug; 10(3):211-3.
Score: 0.001
-
A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma. Cancer. 1992 Feb 15; 69(4):878-82.
Score: 0.001
-
Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs. 1991 Nov; 9(4):353-6.
Score: 0.001
-
A phase I trial of recombinant alpha-2a interferon (Roferon-A) with weekly cisplatinum. Invest New Drugs. 1991 Feb; 9(1):37-9.
Score: 0.001
-
Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol. 1990 Dec; 8(12):2027-31.
Score: 0.001
-
A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity. J Biol Response Mod. 1990 Oct; 9(5):522-7.
Score: 0.001
-
Imaging with indium111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases. J Clin Oncol. 1990 Jul; 8(7):1246-54.
Score: 0.001
-
Islet cell carcinoma of the pancreas. A study of 98 patients. Cancer. 1990 Jan 15; 65(2):354-7.
Score: 0.001
-
Radiotherapy for anal cancer: experience from 1979-1987. Int J Radiat Oncol Biol Phys. 1989 Dec; 17(6):1153-60.
Score: 0.001
-
Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res. 1989 Jul 15; 49(14):4057-61.
Score: 0.001
-
Phase I study of recombinant gamma-interferon (rIFN-gamma). J Biol Response Mod. 1988 Oct; 7(5):438-46.
Score: 0.001
-
Hepatic arterial infusion with floxuridine and cisplatin: overriding importance of antitumor effect versus degree of tumor burden as determinants of survival among patients with colorectal cancer. J Clin Oncol. 1986 Sep; 4(9):1356-64.
Score: 0.001
-
The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol. 1986 Jul; 147(1):149-54.
Score: 0.001
-
Phase II trial of acivicin in patients with advanced colorectal carcinoma. Am J Clin Oncol. 1986 Jun; 9(3):189-91.
Score: 0.000
-
Phase I clinical study of nafazatrom. Invest New Drugs. 1986; 4(3):251-5.
Score: 0.000
-
Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract. Oncology. 1985; 42(2):69-71.
Score: 0.000
-
Phase I clinical investigation of homoharringtonine. Cancer Treat Rep. 1984 Sep; 68(9):1085-91.
Score: 0.000
-
Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res. 1984 Aug; 44(8):3608-12.
Score: 0.000
-
Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. Cancer. 1984 May 01; 53(9):1836-40.
Score: 0.000
-
Growth factor enhancement of the in vitro stem cell assay. Recent Results Cancer Res. 1984; 94:253-66.
Score: 0.000
-
High-dose cytosine arabinoside (Ara-C) in colorectal cancer. Br J Cancer. 1983 Dec; 48(6):869-71.
Score: 0.000
-
Phase I study of spirogermanium given daily. J Clin Oncol. 1983 May; 1(5):331-6.
Score: 0.000